The Association of Clinical Research Organizations held its inaugural meeting of the CRO Forum. The Forum was established in October 2014 as the primary vehicle for interaction between the CRO industry and TransCelerate BioPharma.
The Association of Clinical Research Organizations held its inaugural meeting of the CRO Forum. The Forum was established in October 2014 as the primary vehicle for interaction between the CRO industry and TransCelerate BioPharma. ACRO and TransCelerate have mutually agreed to initially establish liaison relationships between four TransCelerate workstreams: risk-based monitoring; shared site qualification and training; common protocol template; and quality management system.
The Forum elected as its first Chairman Dr. Alan Metz, Senior Vice President and Managing Director, Strategic Partnerships, at Quintiles. As Vice Chair, the Forum elected Amy Kissam, Executive Director, Global Operational Management, at INC Research. In addition, the CRO Forum selected senior subject matter experts to serve as liaisons to each of the workstreams, and will be supported by working groups consisting of subject matter experts from across the Forum membership.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.